openPR Logo
Press release

Investigation announced for Investors in shares of Vaccinex, Inc. (NASDAQ: VCNX)

08-20-2019 06:36 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Vaccinex, Inc. (NASDAQ: VCNX) shares over potential securities laws violations by Vaccinex, Inc.

An investigation for investors in Vaccinex, Inc. (NASDAQ: VCNX) shares over potential securities laws violations by Vaccinex, Inc.

An investigation was announced on behalf of investors of Vaccinex, Inc. (NASDAQ: VCNX) shares over potential securities laws violations by Vaccinex, Inc.

Investors who purchased shares of Vaccinex, Inc. (NASDAQ: VCNX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vaccinex, Inc. (NASDAQ: VCNX) concerning whether a series of statements by Vaccinex, Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Rochester, NY based Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. On August 9, 2018, Vaccinex, Inc. announced the pricing for its initial public offering. Vaccinex, Inc sold 3.33 million shares at $12.00 per share. Since then shares of Vaccinex, Inc. (NASDAQ: VCNX) declined to as low as $3.94 per share on July 26, 2019.

Those who purchased shares of Vaccinex, Inc. (NASDAQ: VCNX) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Vaccinex, Inc. (NASDAQ: VCNX) here

News-ID: 1824099 • Views: 1702

More Releases from Shareholders Foundation

ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) Investor Alert: Deadline in …
A deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) over alleged securities laws violations. Investors who purchased shares of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSEArca: UCO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Forescout Technolog …
An investigation was announced for long-term investors in shares of Forescout Technologies, Inc. (NASDAQ: FSCT) concerning potential breaches of fiduciary duties by certain directors and officers of Forescout Technologies, Inc.. Investors who are current long term investors in Forescout Technologies, Inc. (NASDAQ: FSCT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ:
Investigation announced for Long-Term Investors in shares of Hebron Technology C …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Hebron Technology Co., Ltd.. Investors who are current long term investors in Hebron Technology Co., Ltd. (NASDAQ: HEBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: HEBT stocks follows a lawsuit filed against Hebron
Investigation announced for Investors in shares of CrossFirst Bankshares, Inc. ( …
An investigation was announced concerning potential securities laws violations by CrossFirst Bankshares, Inc. in connection with certain financial statements. Investors who purchased shares of CrossFirst Bankshares, Inc. (NASDAQ: CFB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by CrossFirst Bankshares, Inc. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Vaccinex

Global Antibody Library Technologies Market to Represent US$ 172.9 Mn by 2026
Posted on September 11, 2017 by Persistence Market Research Antibody Library Technologies Market to Represent US$ 172.9 Mn by 2026 “Owing to the limitation and shortcomings of the conventional molecular display technologies, medical research organizations are now shifting towards new age display less’ technologies, capable of isolating antibodies up to subnanomolar affinities.” – Analyst, Persistence Market Research Demand for antibody library technologies is expected to surge, as the arrival of advanced antibodies and
Global Antibody Library Technologies Market 2016-2024: Phage Display Segment by …
Collaborations and cross-licensing are the key strategies adopted by a majority of players in the global antibody library technologies market. In a new publication titled Antibody Library Technologies Market: Global Industry Analysis and Forecast, 2016-2024, the analysts at Persistence Market Research have observed that antibodies being a most successful biotechnology drug class, pharmaceutical companies are striving to add antibodies to their pipeline in order to alleviate patent cliff. While studying
Global Autoimmune Drugs Market Will Grow At A CAGR Of 5.57% For The Period From …
Researchmoz added Most up-to-date research on "Global Autoimmune Drugs Market Will Grow At A CAGR Of 5.57% For The Period From 2016 - 2020" to its huge collection of research reports. Autoimmune diseases are immunological disorders that occur when the immune system attacks and destroys healthy tissues in the body rather than foreign bodies, causing significant pain, inflammation, and organ damage. These diseases can affect the nervous system, cardiovascular system, and
Antibody Library Technologies Market Size to Expand at 4.4% CAGR by 2026
“Owing to the limitation and shortcomings of the conventional molecular display technologies, medical research organizations are now shifting towards new age display less’ technologies, capable of isolating antibodies up to subnanomolar affinities.” – Analyst, Persistence Market Research Demand for antibody library technologies is expected to surge, as the arrival of advanced antibodies and their display technologies continue to reduce complexities of life science and biotechnology research. Persistence Market Research (PMR),
Global Antibody Library Technologies Market Worth US$ 172.9 Mn in Revenues by 20 …
Demand for antibody library technologies is expected to surge, as the arrival of advanced antibodies and their display technologies continue to reduce complexities of life science and biotechnology research. Persistence Market Research (PMR), in its latest report, projects that the global antibody library technologies market revenue will increase at a CAGR of 4.4% between 2016 and 2024. Some of the latest antibody library design and selection methods enable easy
Asia Pacific and Middle East to lead Epidermal Growth Factor Receptor (EGFR) Ant …
EGFR is the primary receptor recognized in a group of receptors and is a cell surface protein that binds to epidermal growth factor. EGFR is a cell membrane growth factor receptor characterized by tyrosine kinase receptor which plays very important role in the control of key cellular transduction pathways in both normal and cancerous cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been developed in